Enterome to move its research laboratories

Establishing labs in France's biocluster Genopole

21-Sep-2017 - France

Enterome, a pioneer of innovative therapies for microbiome-related diseases announced that the Company is moving its research laboratories to Genopole, a leading biocluster dedicated to biotechnology and research in genomics and genetics. The new laboratories brings Enterome closer to its existing and potential new partners and provides opportunities to extend its scientific expertise and network to develop its business further.

About 15 of the 40 people employed by Enterome will work permanently at Genopole in laboratories dedicated to the discovery and development of innovative therapeutic products derived from the gut microbiome.

Pierre Belichard, CEO of Enterome, said: “The strategic relocation of our laboratories is a key step for developing our technology platform. Genopole is recognised internationally for the quality of its facilities and the professionalism of the technical team, which was a key factor in our decision to make our research headquarters at Genopole.”

The gut microbiome makes an important contribution to maintaining an individuals’ health as it plays a crucial role in building natural immunity. The latest discoveries have allowed the scientific community to characterise some of the functions of the gut bacteria and the understanding of the relationship between the microbiome and human health is becoming more and more important for the development of a new generation of drugs and diagnostics.

Understanding the mechanism of diseases linked to the dysfunction of the gut microbiome is at the heart of Enterome’s metagenomics research platform. By studying the key molecular mechanisms of the bacteria/host interaction, Enterome believes it can use this information to develop innovative drugs and diagnostics that will provide patients with better outcomes to their diseases.

Jean-Marc Grognet, CEO of Genopole, said: “We are delighted to welcome Enterome to our laboratories facilities at Genopole. The study of the microbiome is very important for understanding diseases such as Crohn’s disease, cancers, diabetes, gastro-intestinal disorders and metabolic diseases; and is aligned with our strategy to support research that reflects personalised medicine.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances